Literature DB >> 14506020

Rapid direct method for monitoring antibiotics in a mouse model of bacterial biofilm infection.

Jagath L Kadurugamuwa1, Lin V Sin, Jun Yu, Kevin P Francis, Richard Kimura, Tony Purchio, Pamela R Contag.   

Abstract

We have developed a rapid, continuous method for monitoring the effectiveness of several antibacterial agents in real time, noninvasively, by using a recently described mouse model of chronic biofilm infection (J. L. Kadurugamuwa et al., Infect. Immun. 71:882-890, 2003), which relies on biophotonic imaging of bioluminescent bacteria. To facilitate real-time monitoring of infection, we used a Staphylococcus aureus isolate that was made bioluminescent by inserting a modified lux operon into the bacterial chromosome. This bioluminescent reporter bacterium was used to study the antimicrobial effects of several antibiotics belonging to different molecular families. Treatment with rifampin, tobramycin, and ciprofloxacin was started 7 days after subcutaneous implantation of catheters precolonized with 10(4) CFU of S. aureus. Three different doses of antibiotics were administered twice a day for 4 consecutive days. The number of metabolically active bacteria in untreated mice and the tobramycin- and ciprofloxacin-treated groups remained relatively unchanged over the 4-week observation period, indicating poor efficacies for tobramycin and ciprofloxacin. A rapid dose-dependent decline in metabolic activity in rifampin-treated groups was observed, with almost a 90% reduction after two doses and nearly undetectable levels after three doses. The disappearance of light emission correlated with colony counts. After the final treatment, cell numbers rebounded as a function of concentration in a time-dependent manner. The staphylococci isolated from the catheters of mice treated with rifampin were uniformly resistant to rifampin but retained their in vitro susceptibilities to tobramycin and ciprofloxacin. Since the metabolic activities of viable cells and a postantibiotic effect could be detected directly on the support matrix nondestructively and noninvasively, the methodology is specifically appealing for investigating the effects of antibiotics on biofilms in vivo. Moreover, our study points to the possible use of biophotonic imaging for the detection of the development of resistance to therapeutic agents during treatment of chronic infections in vivo.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14506020      PMCID: PMC201124          DOI: 10.1128/AAC.47.10.3130-3137.2003

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  46 in total

1.  Validation of a noninvasive, real-time imaging technology using bioluminescent Escherichia coli in the neutropenic mouse thigh model of infection.

Authors:  H L Rocchetta; C J Boylan; J W Foley; P W Iversen; D L LeTourneau; C L McMillian; P R Contag; D E Jenkins; T R Parr
Journal:  Antimicrob Agents Chemother       Date:  2001-01       Impact factor: 5.191

Review 2.  Riddle of biofilm resistance.

Authors:  K Lewis
Journal:  Antimicrob Agents Chemother       Date:  2001-04       Impact factor: 5.191

Review 3.  Guidelines for the management of intravascular catheter-related infections.

Authors:  L A Mermel; B M Farr; R J Sherertz; I I Raad; N O'Grady; J S Harris; D E Craven
Journal:  Clin Infect Dis       Date:  2001-04-03       Impact factor: 9.079

4.  On-line monitoring of growth of Escherichia coli in batch cultures by bioluminescence.

Authors:  F Marincs
Journal:  Appl Microbiol Biotechnol       Date:  2000-05       Impact factor: 4.813

Review 5.  Novel approaches to monitor bacterial gene expression in infected tissue and host.

Authors:  S H Lee; A Camilli
Journal:  Curr Opin Microbiol       Date:  2000-02       Impact factor: 7.934

6.  Biofilm culture of Pseudomonas aeruginosa expressing lux genes as a model to study susceptibility to antimicrobials.

Authors:  A Parveen; G Smith; V Salisbury; S M Nelson
Journal:  FEMS Microbiol Lett       Date:  2001-05-15       Impact factor: 2.742

Review 7.  Bacterial biofilms: a common cause of persistent infections.

Authors:  J W Costerton; P S Stewart; E P Greenberg
Journal:  Science       Date:  1999-05-21       Impact factor: 47.728

8.  Use of pharmacodynamic indices to predict efficacy of combination therapy in vivo.

Authors:  J W Mouton; M L van Ogtrop; D Andes; W A Craig
Journal:  Antimicrob Agents Chemother       Date:  1999-10       Impact factor: 5.191

9.  Visualizing pneumococcal infections in the lungs of live mice using bioluminescent Streptococcus pneumoniae transformed with a novel gram-positive lux transposon.

Authors:  K P Francis; J Yu; C Bellinger-Kawahara; D Joh; M J Hawkinson; G Xiao; T F Purchio; M G Caparon; M Lipsitch; P R Contag
Journal:  Infect Immun       Date:  2001-05       Impact factor: 3.441

10.  Monitoring bioluminescent Staphylococcus aureus infections in living mice using a novel luxABCDE construct.

Authors:  K P Francis; D Joh; C Bellinger-Kawahara; M J Hawkinson; T F Purchio; P R Contag
Journal:  Infect Immun       Date:  2000-06       Impact factor: 3.441

View more
  41 in total

Review 1.  Noninvasive biophotonic imaging for studies of infectious disease.

Authors:  Nuria Andreu; Andrea Zelmer; Siouxsie Wiles
Journal:  FEMS Microbiol Rev       Date:  2010-10-19       Impact factor: 16.408

2.  In vivo monitoring of Staphylococcus aureus biofilm infections and antimicrobial therapy by [18F]fluoro-deoxyglucose-MicroPET in a mouse model.

Authors:  Victoria Garrido; María Collantes; Montserrat Barberán; Iván Peñuelas; Javier Arbizu; Beatriz Amorena; María-Jesús Grilló
Journal:  Antimicrob Agents Chemother       Date:  2014-08-25       Impact factor: 5.191

3.  Real-time in vivo bioluminescent imaging for evaluating the efficacy of antibiotics in a rat Staphylococcus aureus endocarditis model.

Authors:  Yan Q Xiong; Julie Willard; Jagath L Kadurugamuwa; Jun Yu; Kevin P Francis; Arnold S Bayer
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

4.  Use of a bioluminescent Pseudomonas aeruginosa strain within an in vitro microbiological system, as a model of wound infection, to assess the antimicrobial efficacy of wound dressings by monitoring light production.

Authors:  R M S Thorn; S M Nelson; J Greenman
Journal:  Antimicrob Agents Chemother       Date:  2007-07-16       Impact factor: 5.191

5.  Quantum dot probes for bacteria distinguish Escherichia coli mutants and permit in vivo imaging.

Authors:  W Matthew Leevy; Timothy N Lambert; James R Johnson; Joshua Morris; Bradley D Smith
Journal:  Chem Commun (Camb)       Date:  2008-04-10       Impact factor: 6.222

6.  Expression of flagella is coincident with uropathogenic Escherichia coli ascension to the upper urinary tract.

Authors:  M Chelsea Lane; Christopher J Alteri; Sara N Smith; Harry L T Mobley
Journal:  Proc Natl Acad Sci U S A       Date:  2007-10-09       Impact factor: 11.205

7.  In vitro and in vivo validation of ligA and tarI as essential targets in Staphylococcus aureus.

Authors:  Karin Streker; Tina Schäfer; Christoph Freiberg; Heike Brötz-Oesterhelt; Jörg Hacker; Harald Labischinski; Knut Ohlsen
Journal:  Antimicrob Agents Chemother       Date:  2008-09-22       Impact factor: 5.191

8.  Reduction of astrogliosis by early treatment of pneumococcal meningitis measured by simultaneous imaging, in vivo, of the pathogen and host response.

Authors:  Jagath L Kadurugamuwa; Kshitij Modi; Olivier Coquoz; Brad Rice; Steven Smith; Pamela R Contag; Tony Purchio
Journal:  Infect Immun       Date:  2005-12       Impact factor: 3.441

9.  Near-infrared fluorescence imaging as an alternative to bioluminescent bacteria to monitor biomaterial-associated infections.

Authors:  Nina Dinjaski; Shalu Suri; Jaione Valle; Susan M Lehman; Iñigo Lasa; María Auxiliadora Prieto; Andrés J García
Journal:  Acta Biomater       Date:  2014-03-13       Impact factor: 8.947

10.  In vivo imaging of bioluminescent Escherichia coli in a cutaneous wound infection model for evaluation of an antibiotic therapy.

Authors:  Samir Jawhara; Serge Mordon
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.